Ravi K. Amaravadi, MD
Medical Oncology
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 3rd Floor West
Headshot of Ravi K. Amaravadi, MD
Penn Medicine Provider

About me

  • Associate Director, Translational Research, Abramson Cancer Center
  • Co-Director, UPenn/Wistar Skin Cancer SPORE
  • Tara Miller Professor of Melanoma Research and Patient Care

Education and training

  • Medical School: Johns Hopkins University School of Medicine
  • Residency: Mass General Brigham Healthcare Center - Chestnut Hill
  • Fellowship: University of Pennsylvania Health System

What my patients think about me

Average Rating

206 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Anonymous
March 2026
referred to another dr for continued care.
Anonymous
March 2026
very kind and thoughtful and encouraging
Anonymous
February 2026
very thorough in explaining the nature of my medical condition
Anonymous
February 2026
professionalism & very informative. took time to answer all questions

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: On the medical staff, but does not have privileges to treat patients in the hospital.
Dr. Amaravadi is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Wei S, Deng Y, Lee J, Lan H, Yang Z, Labrie M, Betts CB, Duan H, Tate B, Pucilowska J, Frederick D, Lawless AR, Sharova T, Yang Y, Hu W, Beasley GM, Schuchter LM, Wang X, Xu W, Yong G, Vandenberg MEG, Torigian DA, Sivagnanam S, Du K, Sugarman E, McGettigan S, Zheng C, Al-Rohil RN, Selim MA, Datto MB, López GY, Nair SK, Ashley DM, Xu X, Amaravadi RK, Karakousis GC, O'Rourke DM, Brem S, O'Malley BW, Demirkan G, Yu S, Lu Y, Camp T, Patterson JA, Wei Z, Corless C, Gabrilovich DI, Mou Y, Flaherty KT, Coussens LM, Boland G, Herlyn M, Mills G, Liu L, Zhang G. A longitudinal, multi-omic atlas reveals the emergence of a spatially organized immunosuppressive ecosystem in resistant melanoma , Cell Rep Med: 2026


Wang H, Liu S, Sinha P, Liu F, Zhang X, Guo Y, Goncalves B, Zheng Q, Mou H, Yang J, Huang L, Miao F, Zeng T, Karakousis G, Huang AC, Mitchell T, Amaravadi R, Schuchter L, Milone M, Guo W, June C, Herlyn M, Fan Y, Xu X. DR5 CAR-T cells target melanoma and suppress MDSCs with minimal toxicity , Mol Ther, 34: 2026,1465-1482


Wang SY, Turner G, Valdes-Morales KL, Hunter ER, Kim M, Tran VA, Polen K, Haynes D, Miller CJ, Etzkorn JR, Sobanko JF, Walker JL, Zhang J, Brody RM, Cannady SB, Rajasekaran K, Farwell DG, Miura JT, Karakousis GC, Lukens JR, Amaravadi RK, Schuchter LM, Mitchell TC, Higgins HW 2nd, Carey RM. Accuracy of Sentinel Lymph Node Biopsy to Predict Nodal Metastasis in Head and Neck Merkel Cell Carcinoma , JAMA Otolaryngol Head Neck Surg, 152: 2026,313-322


Messing I, Linkowski L, Riina MD, Berger M, Baron J, Wang X, Kallan M, Hubbeling HG, Lustig RA, Dorsey JF, Kurtz G, Nagda S, Lukens JN, Flowers A, Lee JYK, Amankulor NM, Jackson C, Mohan S, Amaravadi RK, Schuchter LM, Huang AC, Mitchell TC, Alonso-Basanta M, Lebow ES. Outcomes after SRS and ipilimumab plus nivolumab for melanoma brain metastases following prior immune checkpoint inhibitor or targeted therapy , Oncologist, 31: 2026,oyag043


O'Reilly EM, Cabanski CR, Lyman JP, Wainberg ZA, Fisher GA, Wolff RA, Ko AH, O'Hara MH, Spencer CN, Yu JX, Da Silva DM, Padrón LJ, Arnott J, Fairchild J, Moore JS, Peng B, Hoos WA, O'Donnell-Tormey J, Boffo S, Dugan U, Kimmelman AC, Amaravadi RK, Vonderheide RH. Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated metastatic pancreatic adenocarcinoma , J Immunother Cancer, 14: 2026,e012864


Wang G, Yoon D, Nandi A, Patel K, Azar T, Kim J, Han NA, Nickie A, Park S, Wang K, Yan P, Divaker S, Tabita-Martinez J, Giles L, Carberry M, Beltra JC, Painter MM, Alanio C, Amaravadi RK, Schuchter LM, Carreno BM, Linette GP, Elder DE, Brody RM, Gimotty P, Miura JT, Karakousis GC, Xu X, Mitchell TC, Huang AC. Antigen-specific profiling identifies T-bet(+) melanoma-specific CD8(+) T cells associated with response to neoadjuvant PD-1 blockade , Cancer Cell, 44: 2026,221-234


Trifoi MD, Morales KV, Frankel D, Lin SK, Deitermann AM, Haynes D, Lubeck M, Etzkorn JR, Sobanko JF, Giordano CN, Walker JL, Zhang J, Lewis DJ, Higgins HW 2nd, Miura JT, Karakousis GC, Rajasekaran K, Cannady SB, Brody RM, Mitchell TC, Amaravadi RK, Lukens JN, Miller CJ. Compliance with guidelines and timeliness of sentinel lymph node biopsy for Merkel cell carcinoma treated with Mohs micrographic surgery versus conventional excision at a tertiary academic center , J Am Acad Dermatol: 2026


Crissey MAS, Versace A, Bhardwaj M, Jain V, Liu S, Singh A, Beer LA, Tang HY, Villanueva J, Gimotty PA, Xu X, Amaravadi RK. Divergent effects of acute and chronic PPT1 inhibition in melanoma , Autophagy: 2025


Guo Y, Wang H, Liu S, Zhang X, Zhu X, Huang L, Zhong W, Guan L, Chen Y, Xiao M, Ou L, Yang J, Chen X, Huang AC, Mitchell T, Amaravadi R, Karakousis G, Miura J, Schuchter L, Flowers A, Zheng Q, Mou H, Gimotty P, Herlyn M, Guo W, Xu X. Engineered extracellular vesicles with DR5 agonistic scFvs simultaneously target tumor and immunosuppressive stromal cells , Sci Adv, 11: 2025,eadp9009


Ma KL, Mitchell TC, Dougher M, Sharon CE, Tortorello GN, Elder DE, Morgan EE, Gimotty PA, Huang AC, Amaravadi RK, Schuchter LM, Flowers A, Miura JT, Karakousis GC, Xu X. Tumor-Infiltrating Lymphocytes in Necrotic Tumors after Melanoma Neoadjuvant Anti-PD-1 Therapy Correlate with Pathologic Response and Recurrence-Free Survival , Clin Cancer Res, 30: 2024,4987-4994